Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020

Rhea-AI Summary

Pulmonx Corporation (NASDAQ: LUNG) will release its third-quarter financial results on November 10, 2020, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company specializes in minimally invasive treatments for lung disease, particularly for severe emphysema/COPD patients. The Zephyr® Endobronchial Valve, part of its treatment solutions, has received FDA pre-market approval and is available in over 25 countries with more than 80,000 valves used on over 20,000 patients.

Positive

• Zephyr Valve has received FDA pre-market approval as a breakthrough device.
• The Zephyr Valve is commercially available in over 25 countries.
• More than 80,000 valves have been used to treat over 20,000 patients.

Negative

• None.

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Tuesday, November 10, 2020. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 7802229. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx® Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for lung disease. The Pulmonx solution, which is comprised of the Zephyr® Endobronchial Valve (Zephyr Valve), the Chartis® Pulmonary Assessment System (Chartis System) and the StratX® Lung Analysis Platform, is designed to treat severe emphysema/COPD patients who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is now commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information, visit www.Pulmonx.com.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

When will Pulmonx release its third-quarter financial results?

Pulmonx will release its third-quarter financial results on November 10, 2020, after market close.

What time is the conference call regarding Pulmonx's financial results?

The conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET on November 10, 2020.

What is the primary product of Pulmonx Corporation?

Pulmonx primarily offers the Zephyr® Endobronchial Valve for treating severe emphysema/COPD.

How many countries is the Zephyr Valve available in?

The Zephyr Valve is available in over 25 countries.

How many Zephyr Valves have been used in treatment?

More than 80,000 Zephyr Valves have been used to treat over 20,000 patients.